Yuan ZB, Fang HB, Feng QK, Li T, Li J. Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study. World J Gastroenterol 2022; 28(15): 1574-1587 [PMID: 35582131 DOI: 10.3748/wjg.v28.i15.1574]
Corresponding Author of This Article
Jie Li, MD, PhD, Director, Doctor, Professor, Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450052, Henan Province, China. ljljdoctor@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2022; 28(15): 1574-1587 Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1574
Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study
Zi-Bo Yuan, Hong-Bo Fang, Quan-Kai Feng, Tao Li, Jie Li
Zi-Bo Yuan, Hong-Bo Fang, Quan-Kai Feng, Tao Li, Jie Li, Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Zi-Bo Yuan, Hong-Bo Fang, Quan-Kai Feng, Jie Li, Henan Research Centre for Organ Transplantation, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Yuan ZB contributed to collect data and draft the manuscript; Fang HB contributed to data analysis; Feng QK and Li T contributed to clinical advice and follow-up survey; Li J contributed to the conception and critically revised the manuscript; all authors read and agreed the final manuscript to be published.
Supported byMedical Science and Technology Project of Henan Province, No. SBGJ2018024.
Institutional review board statement: The study was approved by the Scientific Research and Clinical Trial Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We declare that they have no conflicting interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Li, MD, PhD, Director, Doctor, Professor, Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450052, Henan Province, China. ljljdoctor@126.com
Received: November 17, 2021 Peer-review started: November 17, 2021 First decision: January 9, 2022 Revised: January 18, 2022 Accepted: March 6, 2022 Article in press: March 6, 2022 Published online: April 21, 2022 Processing time: 148 Days and 21.1 Hours
ARTICLE HIGHLIGHTS
Research background
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant tumour originating from intrahepatic bile duct epithelial cells. Recurrence is very common after hepatectomy.
Research motivation
There are few reports on the clinical features and prognostic factors of recurrent ICC, and the treatment strategies for recurrent ICC have not been fully clarified.
Research objectives
The objective of this study was to analyze the prognostic factors of recurrent ICC and to explore treatment strategies.
Research methods
We retrospectively analyzed all ICC patients who underwent hepatectomy at the First Affiliated Hospital of Zhengzhou University between January 2013 and August 2021. We summarized the clinical characteristics of patients with recurrent ICC and assessed prognostic factors by univariate and multivariate analyses.
Research results
Recurrence occurred in 54 of 103 patients with ICC after hepatectomy during the study period. The median OS of patients with recurrent ICC was 4 mo, and the cumulative OS rates at 1, 2, and 3 years after recurrence were 16.1%, 6.7%, and 3.4%, respectively. Multivariate analysis of cumulative survival by the Cox proportional risk model showed that alcohol consumption [hazard ratio (HR) = 4.64, 95% confidence interval (CI): 1.53-14.04, P = 0.007], DFS < 6 mo (HR = 3.47, 95%CI: 1.59-7.60, P = 0.002) and treatment after recurrence (HR = 0.21, 95%CI: 0.08-0.55, P = 0.001) were independent factors for recurrence. Patients who received multimodality therapy had higher survival rates than those who did not (P = 0.026).
Research conclusions
The prognosis of recurrent patients is related to alcohol consumption, DFS < 6 mo and treatment after recurrence. Active and effective multidisciplinary treatment is beneficial to improve the prognosis of patients.
Research perspectives
Multicentre prospective studies are needed to evaluate the efficacy of multidisciplinary treatment in recurrent ICC.